Piper Sandler Maintains Neutral on Hims & Hers Health, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Michael Lavery has maintained a Neutral rating on Hims & Hers Health (HIMS) and increased the price target from $9 to $11.

February 27, 2024 | 3:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains a Neutral rating on Hims & Hers Health but raises the price target from $9 to $11.
The increase in the price target from $9 to $11 by Piper Sandler, while maintaining a Neutral rating, suggests a positive outlook on the stock's value without a strong conviction towards a buy or sell action. This adjustment reflects an expectation of moderate growth or improvement in Hims & Hers Health's stock value in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100